

- susceptibility to hereditary non-medullary thyroid cancer. *Hered Cancer Clin Pract* 20 (2022): 9.
14. Sánchez-Ares M, Cameselle-García S, Abdulkader-Nallib I, et al. Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys. *Front Endocrinol (Lausanne)* 13 (2022): 829103.
 15. Cirello V, Colombo C, Karapanou O, et al. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers. *Front Endocrinol (Lausanne)* 11 (2021): 589340.
 16. Capezzone M, Marchisotta S, Cantara S, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. *Endocr Relat Cancer* 15 (2008): 1075-1081.
 17. Jain K, Basu A. The Multifunctional Protein Kinase C-ε in Cancer Development and Progression. *Cancers (Basel)* 6 (2014): 860-878.
 18. Hafeez BB, Zhong W, Weichert J, et al. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. *Cancer Res* 71 (2011): 2318-2327.
 19. Lang W, Wang H, Ding L, et al. Cooperation between PKC-alpha and PKC-epsilon in the regulation of JNK activation in human lung cancer cells. *Cell Signal* 16 (2004): 457-467.
 20. Mohamed T, Colciago A, Montagnani Marelli M, et al. Protein kinase C epsilon activation regulates proliferation, migration, and epithelial to mesenchymal-like transition in rat Schwann cells. *Front Cell Neurosci* 17 (2023): 1237479.
 21. Zafar S, Khan K, Badshah Y, et al. Exploring the prognostic significance of PKCε variants in cervical cancer. *BMC Cancer* 23 (2023):819. Erratum in: *BMC Cancer* 23 (2023):963.
 22. Lai X, Liang Y, Jin J, et al. Protein kinase C epsilon promotes de novo lipogenesis and tumor growth in prostate cancer cells by regulating the phosphorylation and nuclear translocation of pyruvate kinase isoform M2. *Exp Cell Res* 422 (2023): 113427.
 23. Knauf JA, Ward LS, Nikiforov YE, et al. Isozyme-specific abnormalities of PKC in thyroid cancer: evidence for post-transcriptional changes in PKC epsilon. *J Clin Endocrinol Metab* 87 (2002): 2150-2159.
 24. Zhang X, Li D, Li M, et al. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development. *Int J Cancer* 134 (2014): 257-267.
 25. Capezzone M, Cantara S, Marchisotta S, et al. Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. *J Clin Endocrinol Metab*. 2008 Oct; 93 (2008): 3950-3957.
 26. Morgan AA, Rubenstein E. Proline: the distribution, frequency, positioning, and common functional roles of proline and polyproline sequences in the human proteome. *PLoS One* 8 (2013): e53785.
 27. Debabov VG. The threonine story. *Adv Biochem Eng Biotechnol* 79 (2003): 113-136.
 28. Pacini F, Cantara S, Capezzone M, et al. Telomerase and the endocrine system. *Nat Rev Endocrinol* 7 (2011): 420-430.
 29. Cantara S, Pisu M, Frau DV, et al. Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer. *J Clin Endocrinol Metab* 97 (2012): E1327-1331.
 30. Capezzone M, Cantara S, Marchisotta S, et al. Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer. *J Clin Endocrinol Metab* 96 (2011): E1852-1856.
 31. Messeguer X, Escudero R, Farré D, et al. PROMO: detection of known transcription regulatory elements using species-tailored searches. *Bioinformatics* 18 (2002): 333-334.
 32. Farré D, Roset R, Huerta M, et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. *Nucleic Acids Res* 31 (2003): 3651-3653.
 33. Wang J, Jin J, Liang Y, et al. miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma. *Front Genet* 13 (2022): 978840.
 34. Wang H, Zhan M, Xu SW, et al. miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. *Cell Death Dis* 8 (5): e2770.
 35. Chen Z, Zhou K, Xue J, et al. Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia. *Sci Transl Med* 15 (2023): eabq8513.
 36. Zafar S, Khan K, Badshah Y, et al. Exploring the prognostic significance of PKCε variants in cervical cancer. *BMC Cancer* 23 (2023): 819. Erratum in: *BMC Cancer* 23 (2023): 963.
 37. Yang D, He Y, Wu B, et al. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma. *Cancer Biomark* 29 (2020): 399-416.

38. Huang B, Fu SJ, Fan WZ, et al. PKC ϵ inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. *Cancer Lett* 376 (2016): 148-154.
39. Knauf JA, Elisei R, Mochly-Rosen D, et al. Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. *J Biol Chem* 274 (1999): 23414-23425.
40. Anderson MS, Su MA. AIRE expands: new roles in immune tolerance and beyond. *Nat Rev Immunol* 16 (2016): 247-258.
41. van Laar GG, van Hamburg JP, Tas SW. Extrathymic AIRE-expressing cells: Friends or foes in autoimmunity and cancer? *Autoimmun Rev* 21 (2022): 103141.
42. Nguyen CTK, Sawangarun W, Mandasari M, et al. AIRE is induced in oral squamous cell carcinoma and promotes cancer gene expression. *PLoS One* 15 (2020) :e0222689.
43. Kalra R, Bhagyaraj E, Tiwari D, et al. AIRE promotes androgen-independent prostate cancer by directly regulating IL-6 and modulating tumor microenvironment. *Oncogenesis* 7 (2018): 43.